Risk factor
Considerable default risk
Profitability factor
Solid dividends
About
Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV
Buy
Sell